Persistent interactions between biguanide-based compound NB325 and CXCR4 result in prolonged inhibition of human immunodeficiency virus type 1 infection
- PMID: 20231400
- PMCID: PMC2863618
- DOI: 10.1128/AAC.00934-09
Persistent interactions between biguanide-based compound NB325 and CXCR4 result in prolonged inhibition of human immunodeficiency virus type 1 infection
Abstract
We previously demonstrated that the biguanide-based compound NB325 inhibits human immunodeficiency virus type 1 (HIV-1) infection by interacting with the CXCR4 viral coreceptor. This interaction also appeared to be persistent, since HIV-1 infection was inhibited even when the virus was introduced subsequent to the removal of NB325 from the cell culture medium. The present studies were conducted to determine the extent and mechanism of this prolonged antiviral activity. Persistent inhibition of HIV-1 infection by NB325 was concentration dependent and was apparent up to 8 h after removal of the compound. Flow cytometric analyses of stimulated CD4(+) T lymphocytes exposed to NB325 demonstrated concentration-dependent reductions in CXCR4 extracellular loop 2 epitope recognition that were maintained up to 24 h after removal of the compound. CXCL12-induced chemotaxis was also persistently inhibited following pre-exposure to NB325. These results demonstrate that persistent inhibition of X4 HIV-1 infection by NB325 involves extended perturbation of the viral coreceptor CXCR4.
Figures






Similar articles
-
Cervicovaginal safety of the formulated, biguanide-based human immunodeficiency virus type 1 (HIV-1) inhibitor NB325 in a murine model.J Biomed Biotechnol. 2011;2011:941061. doi: 10.1155/2011/941061. Epub 2011 Oct 24. J Biomed Biotechnol. 2011. PMID: 22131821 Free PMC article.
-
Specific interactions between the viral coreceptor CXCR4 and the biguanide-based compound NB325 mediate inhibition of human immunodeficiency virus type 1 infection.Antimicrob Agents Chemother. 2009 Feb;53(2):631-8. doi: 10.1128/AAC.00866-08. Epub 2008 Dec 1. Antimicrob Agents Chemother. 2009. PMID: 19047650 Free PMC article.
-
Effects of human immunodeficiency virus type 1 infection on CCR5 and CXCR4 coreceptor expression on CD4 T lymphocyte subsets in infants and adolescents.AIDS Res Hum Retroviruses. 2004 Mar;20(3):305-13. doi: 10.1089/088922204322996545. AIDS Res Hum Retroviruses. 2004. PMID: 15117454
-
Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein.Antimicrob Agents Chemother. 2005 Oct;49(10):4296-304. doi: 10.1128/AAC.49.10.4296-4304.2005. Antimicrob Agents Chemother. 2005. PMID: 16189111 Free PMC article.
-
HIV chemokine receptor inhibitors as novel anti-HIV drugs.Cytokine Growth Factor Rev. 2005 Dec;16(6):659-77. doi: 10.1016/j.cytogfr.2005.05.009. Epub 2005 Jul 6. Cytokine Growth Factor Rev. 2005. PMID: 16005254 Review.
Cited by
-
Application and removal of polyanionic microbicide compounds enhances subsequent infection by HIV-1.Virol J. 2012 Jan 26;9:33. doi: 10.1186/1743-422X-9-33. Virol J. 2012. PMID: 22281044 Free PMC article.
-
Novel compounds containing multiple guanide groups that bind the HIV coreceptor CXCR4.Antimicrob Agents Chemother. 2011 Jan;55(1):255-63. doi: 10.1128/AAC.00709-10. Epub 2010 Oct 11. Antimicrob Agents Chemother. 2011. PMID: 20937786 Free PMC article.
-
Infection by CXCR4-Tropic Human Immunodeficiency Virus Type 1 Is Inhibited by the Cationic Cell-Penetrating Peptide Derived from HIV-1 Tat.Int J Pept. 2012;2012:349427. doi: 10.1155/2012/349427. Epub 2012 Jan 29. Int J Pept. 2012. PMID: 22319541 Free PMC article.
-
Structure-activity relationships of polybiguanides with activity against human immunodeficiency virus type 1.Biomed Pharmacother. 2010 Dec;64(10):723-32. doi: 10.1016/j.biopha.2010.10.001. Epub 2010 Nov 4. Biomed Pharmacother. 2010. PMID: 21106331 Free PMC article.
-
Cervicovaginal safety of the formulated, biguanide-based human immunodeficiency virus type 1 (HIV-1) inhibitor NB325 in a murine model.J Biomed Biotechnol. 2011;2011:941061. doi: 10.1155/2011/941061. Epub 2011 Oct 24. J Biomed Biotechnol. 2011. PMID: 22131821 Free PMC article.
References
-
- Balzarini, J., W. G. Brouwer, D. C. Dao, E. M. Osika, and E. De Clercq. 1996. Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus. Antimicrob. Agents Chemother. 40:1454-1466. - PMC - PubMed
-
- Borkow, G., J. Barnard, T. M. Nguyen, A. Belmonte, M. A. Wainberg, and M. A. Parniak. 1997. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J. Virol. 71:3023-3030. - PMC - PubMed
-
- Broxton, P., P. M. Woodcock, and P. Gilbert. 1984. Binding of some polyhexamethylene biguanides to the cell envelope of Escherichia coli ATCC 8739. Microbios 41:15-22. - PubMed
-
- Broxton, P., P. M. Woodcock, and P. Gilbert. 1984. Injury and recovery of Escherichia coli ATCC 8739 from treatment with some polyhexamethylene biguanides. Microbios 40:187-193. - PubMed
-
- Broxton, P., P. M. Woodcock, and P. Gilbert. 1983. A study of the antibacterial activity of some polyhexamethylene biguanides towards Escherichia coli ATCC 8739. J. Appl. Bacteriol. 54:345-353. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials